Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 445

1.

Pheochromocytoma (PHEO) and Paraganglioma (PGL).

Pacak K, Taïeb D.

Cancers (Basel). 2019 Sep 18;11(9). pii: E1391. doi: 10.3390/cancers11091391.

2.

Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels.

Good ML, Malekzadeh P, Ruff SM, Gupta S, Copeland A, Pacak K, Nilubol N, Kebebew E, Patel D.

World J Surg. 2019 Sep 17. doi: 10.1007/s00268-019-05175-9. [Epub ahead of print]

PMID:
31531722
3.

Exploring the link between tumor metabolism and succinate dehydrogenase deficiency: a 18 F-FDOPA PET/CT study in head and neck paragangliomas.

Reichert T, Fahkry N, Lavieille JP, Amodru V, Sebag F, Romanet P, Loundou A, Castinetti F, Pacak K, Montava M, Taïeb D.

Clin Endocrinol (Oxf). 2019 Sep 3. doi: 10.1111/cen.14086. [Epub ahead of print]

PMID:
31479526
4.

Long Intergenic Non-coding RNA Profiles of Pheochromocytoma and Paraganglioma: A Novel Prognostic Biomarker.

Ghosal S, Das S, Pang Y, Gonzales MK, Huynh TT, Yang Y, Taieb D, Crona J, Shankavaram UT, Pacak K.

Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32654. [Epub ahead of print]

PMID:
31469413
5.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I.

Immunity. 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004. No abstract available.

6.

A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position.

Boyd J, Leung AA, Sadrzadeh H, Pamporaki C, Pacak K, Deutschbein T, Fliedner S, Kline GA.

Eur J Endocrinol. 2019 Jul 1. pii: EJE-19-0176.R1. doi: 10.1530/EJE-19-0176. [Epub ahead of print]

PMID:
31370003
7.

Medullary Thyroid Carcinoma: An Update on Imaging.

Kushchayev SV, Kushchayeva YS, Tella SH, Glushko T, Pacak K, Teytelboym OM.

J Thyroid Res. 2019 Jul 7;2019:1893047. doi: 10.1155/2019/1893047. eCollection 2019. Review.

8.

Current experts' views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma.

Taïeb D, Pacak K.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2223-2224. doi: 10.1007/s00259-019-04435-z. Epub 2019 Jul 22.

PMID:
31332495
9.

Synergistic Highly Potent Targeted Drug Combinations in different Pheochromocytoma Models including Human Tumor Cultures.

Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B, William D, Gieldon L, Maurer J, Spöttl G, Rank P, Knösel T, Orth M, Ziegler CG, Aristizabal Prada ET, Rubinstein G, Fassnacht M, Spitzweg C, Grossman AB, Pacak K, Beuschlein F, Bornstein SR, Eisenhofer G, Auernhammer CJ, Reincke M, Nölting S.

Endocrinology. 2019 Jul 19. pii: en.2019-00410. doi: 10.1210/en.2019-00410. [Epub ahead of print]

PMID:
31322702
10.

Postoperative Management in Patients with Pheochromocytoma and Paraganglioma.

Mamilla D, Araque KA, Brofferio A, Gonzales MK, Sullivan JN, Nilubol N, Pacak K.

Cancers (Basel). 2019 Jul 3;11(7). pii: E936. doi: 10.3390/cancers11070936. Review.

11.

Overexpression of a Neuronal Type Adenylyl Cyclase (Type 8) in Sinoatrial Node Markedly Impacts Heart Rate and Rhythm.

Moen JM, Matt MG, Ramirez C, Tarasov KV, Chakir K, Tarasova YS, Lukyanenko Y, Tsutsui K, Monfredi O, Morrell CH, Tagirova S, Yaniv Y, Huynh T, Pacak K, Ahmet I, Lakatta EG.

Front Neurosci. 2019 Jun 18;13:615. doi: 10.3389/fnins.2019.00615. eCollection 2019.

12.

Adipocyte β-arrestin-2 is essential for maintaining whole body glucose and energy homeostasis.

Pydi SP, Jain S, Tung W, Cui Y, Zhu L, Sakamoto W, Jain S, Abel BS, Skarulis MC, Liu J, Huynh T, Pacak K, Caron MG, Gavrilova O, Finkel T, Wess J.

Nat Commun. 2019 Jul 3;10(1):2936. doi: 10.1038/s41467-019-11003-4.

13.

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, Virgolini IJ, Fanti S, Balogova S, Pandit-Taskar N, Pacak K.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137. doi: 10.1007/s00259-019-04398-1. Epub 2019 Jun 29.

PMID:
31254038
14.

More on Ivabradine in Tachycardia with Paraganglioma. Reply.

Malaza G, Brofferio A, Pacak K.

N Engl J Med. 2019 Jun 27;380(26):2590. doi: 10.1056/NEJMc1905730. No abstract available.

PMID:
31242383
15.

Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE.

Wolf KI, Jha A, van Berkel A, Wild D, Janssen I, Millo CM, Janssen MJR, Gonzales MK, Timmers HJKM, Pacak K.

Nucl Med Mol Imaging. 2019 Jun;53(3):223-230. doi: 10.1007/s13139-019-00579-w. Epub 2019 Feb 22.

PMID:
31231443
16.

Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches.

Gieldon L, William D, Hackmann K, Jahn W, Jahn A, Wagner J, Rump A, Bechmann N, Nölting S, Knösel T, Gudziol V, Constantinescu G, Masjkur J, Beuschlein F, Timmers HJ, Canu L, Pacak K, Robledo M, Aust D, Schröck E, Eisenhofer G, Richter S, Klink B.

Cancers (Basel). 2019 Jun 11;11(6). pii: E809. doi: 10.3390/cancers11060809.

17.

Chiari Malformation Type 1 in EPAS1-Associated Syndrome.

Rosenblum JS, Maggio D, Pang Y, Nazari MA, Gonzales MK, Lechan RM, Smirniotopoulos JG, Zhuang Z, Pacak K, Heiss JD.

Int J Mol Sci. 2019 Jun 10;20(11). pii: E2819. doi: 10.3390/ijms20112819.

18.

MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.

Ruff SM, Ayabe RI, Malekzadeh P, Good ML, Wach MM, Gonzales MK, Tirosh A, Nilubol N, Pacak K, Kebebew E, Patel D.

J Surg Res. 2019 May 27;243:1-7. doi: 10.1016/j.jss.2019.04.086. [Epub ahead of print]

PMID:
31146085
19.

A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An Epas1 Gain-of-Function Mutation.

Wang H, Cui J, Yang C, Rosenblum JS, Zhang Q, Song Q, Pang Y, Fang F, Sun M, Dmitriev P, Gilbert MR, Eisenhofer G, Pacak K, Zhuang Z.

Cancers (Basel). 2019 May 14;11(5). pii: E667. doi: 10.3390/cancers11050667.

20.

The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40.

Caisova V, Li L, Gupta G, Jochmanova I, Jha A, Uher O, Huynh TT, Miettinen M, Pang Y, Abunimer L, Niu G, Chen X, Ghayee HK, Taïeb D, Zhuang Z, Zenka J, Pacak K.

Cancers (Basel). 2019 May 11;11(5). pii: E654. doi: 10.3390/cancers11050654.

Supplemental Content

Loading ...
Support Center